Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease?: Implications for therapeutic blockade of the renin-angiotensin system

被引：140
作者：
Lévy, BI [1 ]
机构：
[1] Univ Paris 07, IFR Circulat Lariboisiere, Hop Lariboisiere, INSERM,U541, F-75475 Paris 10, France
来源：
CIRCULATION | 2004年 / 109卷 / 01期
关键词：
receptors; angiotensin; cardiovascular diseases; hypertrophy;
D O I：
10.1161/01.CIR.0000096609.73772.C5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：8 / 13
页数：6
相关论文
共 54 条
[31]   Tissue angiotensin II and endothelin-1 modulate differently the response to flow in mesenteric resistance arteries of normotensive and spontaneously hypertensive rats [J].
Matrougui, K ;
Lévy, BI ;
Henrion, D .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (03) :521-526
[32]   Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases [J].
Matsubara, H .
CIRCULATION RESEARCH, 1998, 83 (12) :1182-1191
[33]   Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis [J].
Miura, SI ;
Karnik, SS .
EMBO JOURNAL, 2000, 19 (15) :4026-4035
[34]  
Moudgil R, 2002, CAN J CARDIOL, V18, P1107
[35]   Opposing actions of angiotensin II on microvascular growth and arterial blood pressure [J].
Munzenmaier, DH ;
Greene, AS .
HYPERTENSION, 1996, 27 (03) :760-765
[36]   RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial (Retracted article. See vol. 374, pg. 1226, 2009) [J].
Nakao, N ;
Yoshimura, A ;
Morita, H ;
Takada, M ;
Kayano, T ;
Ideura, T .
LANCET, 2003, 361 (9352) :117-124
[37]   Enhanced angiotensin II activity in heart failure - Reevaluation of the counterregulatory hypothesis of receptor subtypes [J].
Opie, LH ;
Sack, MN .
CIRCULATION RESEARCH, 2001, 88 (07) :654-658
[38]   Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats [J].
Otsuka, S ;
Sugano, M ;
Makino, N ;
Sawada, S ;
Hata, T ;
Niho, Y .
HYPERTENSION, 1998, 32 (03) :467-472
[39]   Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [J].
Pfeffer, MA ;
McMurray, JJV ;
Velazquez, EJ ;
Rouleau, JL ;
Kober, L ;
Maggioni, AP ;
Solomon, SD ;
Swedberg, K ;
Van de Werf, F ;
White, H ;
Leimberger, JD ;
Henis, M ;
Edwards, S ;
Zelenkofske, S ;
Sellers, MA ;
Califf, RM ;
Aylward, P ;
Armstrong, P ;
Barvik, S ;
Belenkov, Y ;
Dalby, A ;
Diaz, R ;
Drexler, H ;
Ertl, G ;
Francis, G ;
Hampton, J ;
Harsanyi, A ;
Kvasnicka, J ;
Mareev, V ;
Marin-Neto, J ;
Murin, J ;
Myers, M ;
Nordlander, R ;
Opolski, G ;
Soler-Soler, J ;
Spac, J ;
Stefenelli, T ;
Sugrue, D ;
Van Gilst, W ;
Varshavsky, S ;
Weaver, D ;
Zannad, F ;
Aguilar, D ;
Alvarez, A ;
Al-Taweel, M ;
Anavekar, N ;
Finn, P ;
Lopez-Jimenez, F ;
Mercier, R ;
Lewis, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (20) :1893-1906
[40]   Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II [J].
Pitt, B ;
Poole-Wilson, PA ;
Segal, R ;
Martinez, FA ;
Dickstein, K ;
Camm, AJ ;
Konstam, MA ;
Riegger, G ;
Klinger, GH ;
Neaton, J ;
Sharma, D ;
Thiyagarajan, B .
LANCET, 2000, 355 (9215) :1582-1587
123456